Heme oxygenase and carbon monoxide protect from muscle dystrophy

Mun Chun Chan1,2, Olivia Ziegler1,2, Laura Liu1,2, Glenn C. Rowe1,3, Saumya Das1,2, Leo E. Otterbein4 and Zoltan Arany5*

Abstract

Background: Duchenne muscle dystrophy (DMD) is one of the most common lethal genetic diseases of children worldwide and is 100% fatal. Steroids, the only therapy currently available, are marred by poor efficacy and a high side-effect profile. New therapeutic approaches are urgently needed.

Methods: Here, we leverage PGC-1α, a powerful transcriptional coactivator known to protect against dystrophy in the mdx murine model of DMD, to search for novel mechanisms of protection against dystrophy.

Results: We identify heme oxygenase-1 (HO-1) as a potential novel target for the treatment of DMD. Expression of HO-1 is blunted in the muscles from the mdx murine model of DMD, and further reduction of HO-1 by genetic haploinsufficiency worsens muscle damage in mdx mice. Conversely, induction of HO-1 pharmacologically protects against muscle damage. Mechanistically, HO-1 degrades heme into biliverdin, releasing in the process ferrous iron and carbon monoxide (CO). We show that exposure to a safe low dose of CO protects against muscle damage in mdx mice, as does pharmacological treatment with CO-releasing molecules.

Conclusions: These data identify HO-1 and CO as novel therapeutic agents for the treatment of DMD. Safety profiles and clinical testing of inhaled CO already exist, underscoring the translational potential of these observations.

Keywords: PGC-1α, mdx, Duchenne muscle dystrophy, Heme oxygenase, HO-1, Carbon monoxide

Background

Duchenne muscular dystrophy (DMD) is a common (1 in 3500 boys), X-linked recessive, inexorably lethal disease characterized by acute phases of muscular degeneration and insufficient compensatory regeneration [1]. Diagnosis occurs early in life from noticeable walking difficulty. The disease is 100% fatal. Death occurs by the early twenties from respiratory or cardiac failure caused by damage to the heart and diaphragm muscles. There is no known cure for DMD. DMD is caused by mutations in the dystrophin (DMD) gene that lead to loss of functional protein. Dystrophin protein is a part of the large dystrophin-glycoprotein complex that links the inner cytoskeleton of muscle cells with the extracellular basal lamina. Loss of dystrophin leads to dysfunction and necrosis of mature muscle cells including an increase in membrane damage from mechanical or hypo-osmotic stress and decreased function of plasma membrane proteins including neuronal nitric oxide synthase (nNOS) [1–4]. Though the genetic cause of DMD is known, how dystrophin mutations lead to muscle damage is incompletely understood, nor how to reverse the process. Significant efforts have focused recently on achieving total cure for DMD, including approaches such as exon skipping and most recently CRISPR-mediated genome editing [5–7], but significant hurdles persist. A complementary approach, which may be more imminently tractable, is the possibility of altering the natural course of the disease, via inhibiting degeneration and/or stimulating regeneration of muscle cells.

The transcriptional coactivator peroxisome proliferator-activated receptor gamma coactivator 1-α (PGC-1α) is a powerful activator of broad metabolic programs in various tissues [8–10]. In the skeletal muscle, PGC-1α strongly
induces mitochondrial biogenesis, resulting in mice resistant to fatigue [11, 12]. A number of years ago, crossing mice that transgenically express PGC-1α in the skeletal muscle into the dystrophin-deficient mice (mdx) background, a well-established murine model of DMD, revealed impressive protection against dystrophy [13]. The protection has widely been presumed to result from the strong PGC-1α-mediated induction of neuromuscular junction genes and, in particular of utrophin, a homolog of dystrophin that is known to be protective in DMD models. However, we recently generated mice with muscle-specific expression of peroxisome proliferator-activated receptor gamma coactivator 1-β (PGC-1β), a homolog of PGC-1α, and found that PGC-1β did not induce neuromuscular junction (NMI) genes or utrophin itself and yet was equally protective against dystrophy in the mdx model [14]. This suggested that utrophin was not the key mediator of protection in the PGC-1α transgenic mice. We formally tested this notion by crossing the PGC-1α-expressing mice into an mdx/utrophin−/− background, which at baseline reveal much more pronounced dystrophy, including blunted growth, kyphosis, and early lethality. PGC-1α significantly improved the dystrophic phenotype of these mice, including early lethality [14]. PGC-1α thus potently protects against dystrophy, but not via utrophin.

How does PGC-1α protect against muscle dystrophy, if not via utrophin? We investigate here two possibilities: induction of vasculature and induction of Hmox1, the gene encoding for heme oxygenase (HO-1).

Methods
Animals
All animal experiments were performed according to the procedures approved by the Beth Israel Deaconess Medical Center’s Institutional Animal Care and Use Committee. All experimental animals used were male. C57BL/10ScSn-Dmd<sup>mdx</sup> mice (mdx mice) were obtained from Jackson Laboratories. These mice were crossed with muscle-specific PGC-1α transgenic mice (MCK-PGC-1α), described previously [11]; muscle-specific PGC-1β transgenic mice (MCK-PGC-1β) described previously [15]; or mice with inducible PGC-1α (Ind_PGC-1α) that possess the muscle-specific tetracycline-dependent activator (MCK-tTA), described previously [16], and the PGC-1α coding region under control of the tet-response element promoter (TRE-PGC-1α) transgenic genes, described previously [16]. All of these mice were in C57BL/6 background; progeny were therefore in mixed C57BL/6 and C57BL/10 background. For all experiments, littersmates were used as controls, and male animals were evaluated. mdx, mdx/MCK-PGC-1α, mdx/MCK-PGC-1β, and mdx/Ind_PGC-1α were sacrificed at 9 weeks of age (n = 5 transgenic, 5 controls). Male HMOX<sup>+/−</sup> mice (FVB,129S2(B6)-Hmox1<sup>tm1Poss</sup>/J) were obtained from Jackson Laboratories (JAX008311) and crossed with female C57BL/10ScSn-Dmd<sup>mdx</sup> mice. HMOX<sup>+/−</sup>/mdx animals are therefore in mixed background, and, again, littermates were strictly used for control (n = 8 experimental; 8 control). Ind_tsFLT mice, engineered to express in skeletal muscle inducible sFlt1 in a tet-OFF fashion, have been used by us previously [17] and were generated by crossing transgenic mice expressing tet-inducible sFlt1, previously described [18], with transgenic mice expressing muscle-specific expression of the tTA transactivator, as above. All doxycycline-responsive mice are in a tet-OFF system, and mice were maintained on tetracycline chow throughout pregnancy and development, and switched to regular chow at 5 weeks of age, followed by evaluation and harvesting at 9 weeks of age. Littermate controls were used for all experiments.

Protoporphyrin IX cobalt chloride (CoPP) (Sigma-Aldrich) was dissolved in NaOH (0.2 M) and then adjusted to pH 7.6 with HCl. 10 mg/kg/day of dissolved CoPP was injected three times a week intra-peritoneally into mdx male mice from 5 to 9 weeks of age (n = 10 CoPP; 7 control). Age-matched mdx control mice were injected with HCl-neutralized NaOH (pH 7.6). Male mdx mice were exposed to carbon monoxide (CO) gas at a concentration of 250 ppm for 1 h a day, 5 days a week, for 4 weeks total from 5 to 9 weeks of age. Mice were then sacrificed. Control mdx mice were placed in an equivalent-sized plexiglass box for 1 h a day (n = 8 CO, 8 control). Male mdx mice were injected with 2.5 mg/kg/day of CO-releasing molecule A1 (CORM-A1) from 5 to 9 weeks of age. CORM-A1 was dissolved 5 min before injection freshly each day. Inactivated CORM-A1 was obtained by dissolving CORM-A1 and then piping nitrogen through the solution for 15 min to activate release of all CO. Inactivated CORM-A1 was made fresh every 2 weeks (n = 6 active CORM-A1; 8 inactivated CORM-A1).

Cell culture
Primary satellite cells were isolated and cultured from the entire hind limb of wild-type/control (WT) mice as previously described [19]. Cells were differentiated into myotubes using DMEM with 5% horse serum for 72 h. Cells were then infected with control (GFP) adenovirus (WT) or recombinant PGC-1α adenovirus (Ad-PGC-1α) at multiplicity of infection of 10–30. Ad-PGC-1α contains PGC-1α expressed under control of the CMV promoter and has been described previously [20]; we have used it extensively, with robust induction of PGC-1α expression [17, 21, 22]. Cells were analyzed 48 h later.

Evans blue injection and histological analysis
For Evans blue assay, mice were injected with 1% solution i.p. at a final concentration of 1% volume to body weight.
16 h priors to sacrifice. Tissues were dissected and embedded in OCT compound (VWR) and flash-frozen. Evans blue was analyzed by fluorescence microscopy. Percentage area of Evans blue extravasation in the gastrocnemius was quantified, using ImageJ (NIH), by measuring the area of extravasation in at least ten ×200 images per condition. For purposes of quantifying central nuclei and fiber sizes, sections were stained with rabbit polyclonal anti-laminin antibody (Abcam, ab11575) in order to establish fiber boundaries. We used two different staining techniques to calculate centralized nuclei: (i) frozen sections were stained with anti-laminin and counterstained with DAPI; (ii) tissue was dehydrated and embedded in paraffin and sectioned before H&E staining. In either case, 20 images were taken at ×200 and number of centralized nuclei fibers to total fibers was counted in a blinded fashion. At least 500 fibers across sections from different animals were counted for each condition. For fiber sizes, all sizes were measured using ImageJ software, and 50 bins were created spanning the smallest to largest fiber size across the two comparison groups. For each group, the % of fibers in each bin was then calculated and plotted. Statistical comparison between groups were done using the Mann-Whitney U test.

Serum creatine kinase assay
The blood was collected and serum isolated using heparin-coated collection tubes, either by heart puncture or cheek bleed. Blood was collected and spun down at maximum speed in heparinized tubes, after which serum was collected, flash-frozen, and stored at −80. Serum creatine kinase activity was then determined, simultaneously for all samples in a given experiment, with a Creatine Kinase-SL Assay Kit (Diagnostic Chemicals Limited).

Real-time PCR
Total RNA was isolated from mouse tissue using the TRIzol (Invitrogen) reagent, while RNA from cultured cells were isolated using the Turbocapture (Qiagen) method. Samples for real-time PCR analyses were reverse transcribed (Applied Biosystems), and quantitative real-time PCRs were performed on the cDNAs in the presence of fluorescent dye (SYBR green; Bio-Rad). Relative expression levels were determined using the comparative cycle threshold method. All q-RT-PCR data were normalized to the average expression of three different housekeeping genes, TATA-binding protein (TBP), hypoxanthine phosphoribosyltransferase 1 (HPRT), and β-actin, as we have described previously [23]. Sequences are provided below:

Mouse

| Transcript | Forward Primer | Reverse Primer |
|------------|---------------|---------------|
| HPRT       | GTTAAAGCAGTAGCAGCCACAAA | AAGGGCATATCACAACAAACTT |
| TBP        | CCCTATCACTCTGCGACACCAGC | GTGCAAATGTCTTAGGGTCAGTCCAGCC |

Human

| Transcript | Forward Primer | Reverse Primer |
|------------|---------------|---------------|
| HPRT       | TGGACAGGACTGAAGCTTTTGG | CCAGCACGGTAGCGTAAGCAGCT |
| TBP        | GAGCCAAGAGTGAGGACAGTC | GCTCCCACTATTCGGAAGCT |
| β-actin    | GAGGCGGCGTCACGGGCTT | TCTCCATGTCGACGCAGATT |
| HMOX1      | GCAGAGGGTGATAGAAGGCC | GATGTTGACGGAGACCGCAT |
| HMOX2      | TCAGCGGAAGTGGAAACCTC | AGAAGTCCCTCAGCAAAACTGGT |
| VEGF-A     | AGCCGATGCACTGACAGGACGAGC | GCTCCCACTATTCGGAAGCT |
| PGC-1a     | AGCCCCTAGCAGCAGCGAGGAGC | GCTCCCACTATTCGGAAGCT |

Western blotting
Protein from gastrocnemius (100 μg) was run on a 4–20% polyacrylamide gel, transferred to nitrocellulose membrane, and blotted for heme-oxygenase I using an anti-HMOX1 antibody (AD1-SPA-896, Enzo Life Sciences), followed by goat anti-rabbit antibody conjugated to horse-radish peroxidase (7074, Cell Signaling Technology Inc), followed by detection using ECL Reagent (Cell Signaling Technology Inc). As control, blot was stripped and probed with anti-pan-actin antibody (Cell Signaling Technology Inc). Blots were visualized and quantified with Biorad Image-Lab Software.

Patient biopsies
Biopsies from patients were kindly obtained from the lab of Dr. Louis Kunkel. Biopsies were taken of the vastus lateralis of normal controls and latissimus dorsi of DMD muscle. The WT biopsies were from healthy male subjects ranging from 13 to 32 years of age. Biopsies from DMD patients were from 12 to 20 years of age with different genetic defects in the dystrophin gene.

Statistical analysis
The data were presented as means ± SEM. Statistical analysis was performed with Student’s t test for all in vitro experiments and ANOVAs for all in vivo experiments.
Fiber size comparisons were done using the Mann-Whitney U test. P values of <0.05 were considered statistically significant.

Results

Inhibition of VEGF signaling worsens dystrophy
We showed a number of years ago that PGC-1α powerfully induces angiogenesis in the skeletal muscle [21, 24]. The new vessels are functional, patent, non-leaky, and carry blood [25], PGC-1α thus coordinately induces the consumption of fuel and oxygen (in mitochondria) with the delivery of fuel and oxygen (via blood vessels). Reduced blood flow and ischemia have been proposed to play an important role in DMD models, in part leading to the rationale for the recent use of the vasodilators sildenafil and tadalafil in clinical trials (with, thus far, mixed results). We therefore reasoned that perhaps, PGC-1α exerts its potent anti-dystrophic effects via dramatic increase in vascular density and blood flow. To test this notion, we first generated, in the mdx background, mice that express, in the muscle only and in a tetracycline-inducible manner, a locally secreted soluble VEGF receptor 1 (also known as soluble Fms-like tyrosine kinase 1, sFlt1). This VEGF “trap” neutralizes extracellular VEGF signaling and blocks angiogenesis. These mice, which we name Ind_tsFLT, were generated by breeding transgenic mice expressing tetracycline-inducible sFlt1, a kind gift of Eli Keshet [18], with transgenic mice expressing muscle-specific expression of the tTA transactivator, also previously described [16], all in the mdx background (Fig. 1a). Thus, the mice express the VEGF trap only in the skeletal muscle and only in the absence of doxycycline. Mice were fed doxycycline-containing chow throughout pregnancy, development, and weaning, to maintain the VEGF trap suppressed. At 5 weeks of age, mice were changed to normal chow, leading to robust expression of the VEGF trap in the skeletal muscle (Fig. 1b). Importantly, by virtue of a heparin-binding domain, the VEGF trap does not leak into the circulation or to other tissues (Fig. 1b), as originally reported [18]. Littermate mice that did not contain the sFLT transgene were used as controls and were similarly maintained on doxy-chow and released to normal chow at 5 weeks, thus controlling for any effects of doxycycline chow.

Mdx mice undergo cycles of muscle degeneration and regeneration, most marked during the first 3–10 weeks of life. Muscle degeneration can be detected during this period in a number of fashions, including accumulation of muscle creatine kinase (CK) in serum, and extravasation of Evans blue dye, which normally remains intravascular in the absence of tissue damage. Strikingly,
induction of the VEGF trap in the skeletal muscle of \(mdx\) mice led to a near doubling of serum CK levels (Fig. 1c). This was accompanied by marked increase in EBD extravasation (Fig. 1d). Following muscle degeneration, cycles of regeneration are driven by the activation of resident progenitor cells and their fusion with degenerating myofibers. This process can be detected by the appearance and accumulation of central nuclei, which otherwise normally reside in the periphery of fibers, as well as the accumulation of small regenerated myofibers. Consistent with the increase in muscle damage, induction of the VEGF trap in the skeletal muscle of \(mdx\) mice markedly increased the accumulation of central nuclei (Fig. 1e). These data demonstrate that suppression of VEGF signaling in \(mdx\) mice markedly worsens muscle dystrophy in this model, consistent with the notion that impaired vascular homeostasis worsens dystrophy.

PGC-1α protects against dystrophy independently of angiogenesis

Can suppression of VEGF signaling abrogate the ability of PGC-1α to improve muscle dystrophy? To test this, we used a triple transgenic model, in the background of the \(mdx\) model, whereby both PGC-1α and the VEGF trap are simultaneously induced in the skeletal muscle of \(mdx\) mice upon removal of doxycycline (Fig. 2a). This was achieved by crossing Ind-tsFlt mice with mice containing a third transgene encoding for tetracycline-inducible PGC-1α, a kind gift from Dr. Dan Kelly [16]. Therefore, in these triple transgenic mice, the VEGF trap and PGC-1α are simultaneously induced, only in the skeletal muscle and only in the absence of doxycycline. Induction of PGC-1α alone (without the VEGF trap) led to a robust induction of vascular density, which was completely abrogated with co-induction of the VEGF trap (Fig. 2b), as we have shown before in a non-dystrophic context [17], thus demonstrating the effectiveness of suppression of angiogenesis in this model. We therefore used this system to test the hypothesis that PGC-1α improves muscle dystrophy by virtue of stimulating vascular density. If true, then induction of PGC-1α in the context of simultaneously induced VEGF trap should show no improvement compared to the VEGF trap alone. Strikingly, however, despite the complete block in angiogenesis, the induction of PGC-1α was still able to protect against dystrophy in the presence of the VEGF trap, as shown by reduction of circulating CK (Fig. 2c), reduced extravasation of EB dye (Fig. 2d), and reduced accumulation of central nuclei (Fig. 2e). Thus, these data show...
that suppression of VEGF signaling in mdx mice does not prevent PGC-1α from protecting against muscle dystrophy in this model.

**HO-1 expression is reduced in dystrophic muscle and is rescued by PGC-1α**

How does PGC-1α protect against muscle dystrophy, if not via utrophin, via NMJ induction, or via increases in vascular density? We reasoned that identifying other pathways induced by PGC-1α may point to novel pathways involved in protection against dystrophy. In search of genes induced by PGC-1α that may have protective roles in the skeletal muscle, our attention was caught by Hmox1, the gene encoding for heme oxygenase (HO-1), as a gene of interest. HO-1 degrades the cyclic prosthetic group heme, liberating ferrous iron and yielding biliverdin and gaseous carbon monoxide (CO) in the process. Heme is abundant in the skeletal muscle, present for example in myoglobin and mitochondrial cytochromes. A growing literature supports a protective role for HO-1 in various contexts, though it remains unclear to what extent these benefits accrue from the degradation of toxic heme, the generation of anti-oxidant biliverdin, and/or protective effects of CO [26–28]. We therefore decided to focus attention on HO-1. Interestingly, the Kunkel lab recently identified small molecule inducers of HO-1 as protective in a zebrafish model of DMD, although subsequent experiments raised into question if protection involved increasing HO-1, as originally proposed [29, 30].

Consistent with previous reports, we find induction of mitochondrial (cox5b) and angiogenic (VEGFA) genes,
and utrophin, in quadriceps, gastrocnemius, and tibialis anterior, of mice that transgenically express PGC-1α in the skeletal muscle under control of the muscle creatine kinase promoter (MCK-PGC-1α mice) (Fig. 3a). In addition, we noted a strong threefold induction of Hmox1. Adenoviral delivery of PGC-1α to differentiated primary myotubes induced Hmox1 fourfold (Fig. 3b), indicating that the induction of Hmox1 by PGC-1α is cell autonomous. To assess the role for HO-1 in muscle dystrophy, we first tested its expression in the muscle from mdx mice. As shown in Fig. 3c, d, both transcript and protein expression of HO-1 were depressed more than 50% in the muscle from these mice, compared to age-matched, sex-matched, C57/BL10 mice, purchased from the same vendor and bred and maintained in the same mouse facility and suite as the mdx mice. Evaluation of human muscle biopsies revealed a strong trend for depressed expression of HO-1 (Fig. 3e, P < 0.07) (although these data must be interpreted with caution, in light of small number of samples and variability of biopsy site).

Transgenic expression of PGC-1α in the mdx background reversed this inhibition, inducing Hmox1 transcript and HO-1 protein more than twofold compared to littermate controls not expressing the transgene (Fig. 3f, g). Transgenic expression of PGC-1β in the skeletal muscle also induced HO-1 more than twofold in mdx mice compared to littermate controls not expressing the transgene (Fig. 3g). These data indicate that HO-1 expression is depressed in muscle dystrophy and that induction of PGC-1α can reverse the repression of HO-1.

**Increasing HO-1 expression ameliorates muscle damage, while decreased HO-1 expression exacerbates muscle damage in mdx mice**

In light of the known beneficial effects of PGC-1α in mdx mice, the data above suggested that induction of HO-1 may improve dystrophy in this model. To test this notion, we treated mdx mice with cobalt protoporphyrin (Co-PP), a well-established and powerful inducer of HO-1 expression [31]. Treatment of mdx mice with

---

**Fig. 4** Induction of HO-1 protects against dystrophy. **a** Model. **b, c** Relative gene expression (b) and protein expression (c) of HO-1 in the muscle from mdx mice treated with Co-PP, versus vehicle. Quantification is shown on the right in c. **d–g** Serum creatine kinase levels (d), and % Evans blue extravasation (e), fiber size distribution (f), and % central nuclei (g) in gastrocnemius muscle from mdx mice treated with Co-PP, versus vehicle. n = 8. *P < 0.05, Student’s t test. Scale bar = 50 μm. Error bars indicate ±SEM.
injections of Co-PP three times a week for 4 weeks led to robust induction of HO-1 mRNA and protein expression measured in the gastrocnemius muscle (Fig. 4a–c). Strikingly, accumulation of CK in the serum of *mdx* mice was reduced by 50% (Fig. 4d) by treatment with Co-PP. This was accompanied by visible inhibition of Evans blue dye extravasation in the diaphragm and gastrocnemius (Fig. 4e). Consistent with the inhibition of muscle damage, treatment of *mdx* mice with Co-PP preserved larger myofiber size (Fig. 4f) and markedly reduced the accumulation of central nuclei (Fig. 4g). These data demonstrate that treatment with Co-PP and induction of HO-1 in *mdx* mice markedly improves muscle dystrophy in this model.

The data above indicate that induction of HO-1 is sufficient to protect against muscle dystrophy. To test if HO-1 is also necessary for endogenous adaptation to dystrophy, we crossed mice heterozygous null at the *Hmox1* locus into the *mdx* background (Fig. 5a). Mice lacking HO-1 have been described [32]. Homozygous mice are sometimes viable but display numerous phenotypes, including anemia, abnormal iron storage and metabolism, and chronic inflammation. On the other hand, heterozygous mice are largely normal at baseline. As shown in Fig. 5b, c, the expression of HO-1 mRNA and protein is decreased by 50% in heterozygous mice, indicating haploinsufficiency at this locus. The mice are thus useful to test the role of HO-1 in adaptation to the *mdx* background. No abnormalities were seen in the muscle from *Hmox1*/*−/* mice at baseline. On the other hand, as shown in Fig. 5d, accumulation of CK in the serum was significantly worsened in *Hmox1*/*−/*/*mdx* mice, compared to *mdx* alone. This was accompanied by visibly more Evans blue dye extravasation in the diaphragm and gastrocnemius (Fig. 5e). Evidence of compensatory increases in regeneration was seen with significantly smaller fiber sizes (Fig. 5f) and significantly more central nuclei (Fig. 5g). Haploinsufficiency at the *Hmox1* locus thus worsens dystrophy in *mdx* mice, indicating that HO-1 is required for adaptations to the *mdx* background.

![Fig. 5: Suppression of HMOX1 worsens muscle dystrophy. a] mdx mice were crossed with HMOX1 heterozygotes. b, c Relative gene expression (b) and protein expression (c) of HMOX1 in the muscle from mdx and mdx hmxox +/- mice. Quantification is shown on the right in c. d-g Serum creatine kinase levels (d), and % Evans blue extravasation (e), fiber size distribution (f), and % central nuclei (g) in gastrocnemius muscle from mdx versus mdx hmxox +/- mice. n = 8. *P < 0.05, Student’s t test. Scale bar = 50 μm. Error bars indicate ±SEM.
Carbon monoxide treatment ameliorates muscle damage in mdx mice

By what mechanism does HO-1 improve dystrophy? HO-1 degrades the cyclic prosthetic group heme, liberating ferrous iron and yielding biliverdin and CO gas in the process (Fig. 6a). The benefits of HO-1 could in theory accrue from the degradation of toxic heme, the generation of anti-oxidant biliverdin, and/or protective effects of CO itself. We therefore tested if delivery of CO alone to mdx mice could confer protection against dystrophy. We achieved delivery of CO by two methods: first, inhalation of low-dose CO (250 ppm, 0.025%) and, second, by using CO-releasing molecules (CO-RMs). CORM-A1 is a water soluble CO-releasing molecule with a relatively long half-life (21 min at 37 °C, pH 7.4 [33]). Exposure of mdx mice to ambient low-dose CO for 1 h/day for 4 weeks led to a dramatic improvement in dystrophy, evidenced by marked improvement of Evans blue extravasation in diaphragm, and a 40% reduction in circulating creatine kinase levels (Fig. 6b–d). Hmox1 expression was not induced by CO (Fig. 6e), consistent with mechanistic activity downstream of HO-1. Interestingly, myofiber sizes were not altered with CO exposure (Fig. 6f). In addition, central nuclei were slightly increased (Fig. 6g), suggesting that CO may also affect myoprogenitor proliferation or differentiation.

Treatment of mdx mice with daily injections of CORM-A1 for 4 weeks recapitulated all of the findings seen with inhaled CO, including marked improvements in dystrophy, with a dramatic reduction of Evans blue extravasation, and reduced circulating CK levels (Fig. 7a–c), unaltered expression of Hmox1 (Fig. 7d), unaltered myofiber sizes (Fig. 7e), and slight increase in central myonuclei (Fig. 7f).

Together, these data indicate that delivery of CO, either via inhalation or via pharmaceutical delivery, strongly improves indices of muscle dystrophy.

Fig. 6 Inhaled low-dose carbon monoxide protects against dystrophy. a Schematic of HO-1 enzymatic action. b Mice were placed in chambers containing 250 ppm CO for 1 h per day. c, d Serum creatine kinase (c) and sample Evans blue staining in diaphragm and % Evans blue extravasation in gastrocnemius (d) in mdx mice exposed to CO versus air alone. e Relative expression of the indicated genes in gastrocnemius from mdx mice exposed to CO versus air alone. f, g Fiber size distribution in gastrocnemius (f) and % central nuclei in gastrocnemius muscle (g) from mdx mice exposed to CO versus air alone. n = 8. *P < 0.05, Student’s t test. Scale bar = 50 μm. Error bars indicate ±SEM.
Discussion

We have leveraged here the transcriptional coactivator PGC-1α to identify a novel pathway, involving the heme oxygenase enzyme and its enzymatic product carbon monoxide, as potent protective agents against dystrophy. One of the more appealing and transformative aspects of the work is its potential imminent translatability to the clinical setting. CO has an understandably nefarious public image, but the toxicity of CO occurs at doses orders of magnitude higher than those used here. Indeed, CO is produced endogenously by HO-1 under normal physiology. The safety of CO in humans has been demonstrated in phase I dose escalation with no evidence of toxicity (clinicaltrials.gov NCT01050933, Otterbein personal communication, and [26]). Inhaled CO was also found to be safe in patients with COPD [34]. There are currently ongoing clinical trials of inhaled CO for treatment of adult and neonatal pulmonary hypertension (NCT01523548 and NCT01818843, respectively), ARDS (NCT02425579), post-operative ileus (NCT01050712), idiopathic pulmonary fibrosis (NCT01214187), and cardiac mitochondrial dysfunction (NCT01727167), extensively underscoring the accepted toxicity profile of CO. Importantly, in our experiments and in all of the above studies, inhaled CO is delivered only in intermittent doses, in our case 1 h a day. Translation to the clinic is therefore pragmatically feasible. Patients with DMD often have reduced respiratory capacity, in which case, the dose of delivery CO could be adjusted by measuring diffusing capacity of the lung for carbon monoxide (DLCO), a widely used clinical test. Alternatively, CO-releasing molecules (CO-RMs) may also serve as bioavailable alternatives to inhaled CO, which would both facilitate delivery and allay fears of inhaling a gaseous therapeutic. Our work thus suggests that delivery of CO, either by inhalation of by CO-RMs, could be ready for clinical trials, and/or trials in large animals, to test for efficacy in the treatment of Duchenne muscular dystrophy, and perhaps other dystrophies as well.

How does heme oxygenase protect against dystrophy?

Heme oxygenase degrades the cyclic prosthetic group heme, liberating ferrous iron and yielding biliverdin and
gaseous CO (Fig. 3a). The protective effects of HO-1 could therefore in principle stem from reductions of toxic heme or from beneficial effects elicited by biliverdin, iron, or CO. Mechanistically, we show here that CO alone is sufficient to protect against muscle dystrophy. Additional involvement by the other enzymatic products is also possible, as is suggested for example by the observation that treatment with CO or CORM both led to protection from damage, as determined by CK and EBD leak, but did not lead to larger fibers, in contrast to treatment with HO-1 activators.

How CO itself protects against dystrophy is also of interest and will be the subject of future studies. One possibility is the observation that CO can, in some contexts, promote the formation of NO [26]. NO has been espoused as beneficial in models of dystrophy, perhaps in part via vasodilation and improved local ischemia [3, 4, 35]. Exposure to CO can also change cellular bioenergetics and increase oxygen consumption [36, 37] and can increase mitochondrial biogenesis in the muscle from humans and animals [38, 39]. CO-induced mitochondrial biogenesis may thus contribute to protection against dystrophy and if so may constitute a positive feedback loop with PGC-1α expression.

Although we have focused our attention here on heme oxygenase as a novel therapeutic opportunity, the anti-dystrophy protection that is afforded by PGC-1α is likely multifactorial and is unlikely limited only to the induction of heme oxygenase. Because complete deletion of Hmox1 has diffuse effects, testing the relative contribution of the HO-1 system to PGC-1α-mediated protection will require introducing muscle-specific deletion of Hmox1 into transgenic PGC-1α mice in the mdx background.

Conclusions
In summary, our work highlights a new and actionable approach to the treatment of patients with DMD, including the appealing possibility that low-dose inhalation of CO could provide a novel and simple therapy for this devastating disease.

Abbreviations
CO: Carbon monoxide; CORM-A1: CO-releasing molecule A1; DMD: Duchenne muscular dystrophy; HO: Heme oxygenase; MCK: Muscle creatine kinase; mdx: Dystrophin-deficient mice; NMJ: Neuromuscular junction; nNOS: Nitric oxide synthase; PGC-1α: Peroxisome proliferator-activated receptor gamma coactivator 1-α; PGC-1β: Peroxisome proliferator-activated receptor gamma coactivator 1-β; TRE: tet-response element promoter; tTA: Tetracycline-dependent activator; VEGF: Vascular endothelial growth factor; WT: Wild-type/control

Acknowledgements
We thank Dr. Louis Kunkel for contributing samples from DMD patients.

Funding
The NHLBI (ZA and GCR), the Ellison Foundation (ZA), the MDA (ZA), and the NRSA (SR) supported this work.

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Authors’ contributions
MCC designed and conducted the experiments and wrote and edited the manuscript. GCR, OZ, and LL contributed to conducting experiments. ZA, SD, and LEO contributed to the experimental design. ZA wrote and edited the manuscript. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable

Ethics approval
All animal experiments were performed according to the procedures approved by the Beth Israel Deaconess Medical Center’s Institutional Animal Care and Use Committee.

Author details
1Cardiovascular Institute, Beth Israel Deaconess Medical Center, Boston, MA, USA. 2Current address: Cardiovascular Institute, Massachusetts General Hospital, Boston, MA, USA. 3Present Address: Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. 4Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA. 5Cardiovascular Institute and Institute Diabetes Obesity and Metabolism, Smilow Center for Translational Research, Perelman School of Medicine, University of Pennsylvania, 11th floor, 3400 Civic Blvd, Philadelphia 19104, PA, USA.

Received: 29 July 2016 Accepted: 18 November 2016 Published online: 28 November 2016

References
1. Guiraud S, et al. The pathogenesis and therapy of muscular dystrophies. Annu Rev Genomics Hum Genet. 2015;16:281–308.
2. Fairclough RJ, Basea A, Davies KE. Progress in therapy for Duchenne muscular dystrophy. Exp Physiol. 2011;96(11):1011–13.
3. Brennan JE, et al. Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. Cell. 1995;82(5):743–52.
4. Kobayashi YM, et al. Sarcolemma-localized nNOS is required to maintain activity after mild exercise. Nature. 2008;456(7221):407–11.
5. Nelson CE, et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science. 2016;351(6271):403–7.
6. Long C, et al. Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science. 2016;351(6271):400–3.
7. Chan MC, et al. The many roles of PGC-1alpha in muscle—recent developments. Metabolism. 2014;63(4):441–51.
8. Handschin C, Spiegelman BM. Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr Rev. 2006;27(7):728–35.
9. Rowe GC, Jiang A, Arany Z. PGC-1 coactivators in cardiac development and disease. Circ Res. 2011;107(7):825–38.
10. Lin J, et al. Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature. 2002;418(6899):797–801.
11. Calvo JA, et al. Muscle-specific expression of PPARgamma coactivator-1alpha improves exercise performance and increases peak oxygen uptake. J Appl Physiol. 2008;104(5):1304–12.
12. Handschin C, et al. PGC-1alpha regulates the neuromuscular junction program and ameliorates Duchenne muscular dystrophy. Genes Dev. 2007;21(7):770–83.
13. Chan MC, et al. Post-natal induction of PGC-1alpha protects against severe muscle dystrophy independently of utrophin. Skelet Muscle. 2014;4(1):2.
14. Arany Z, et al. The transcriptional coactivator PGC-1beta drives the formation of oxidative type IIX fibers in skeletal muscle. Cell Metab. 2007;5(1):35–46.
16. Russell LK, et al. Cardiac-specific induction of the transcriptional coactivator peroxisome proliferator-activated receptor gamma coactivator-1alpha promotes mitochondrial biogenesis and reversible cardiomyopathy in a developmental stage-dependent manner. Circ Res. 2004;94(4):525–33.

17. Rowe GC, et al. PGC-1alpha induces SPP1 to activate macrophages and orchestrate functional angiogenesis in skeletal muscle. Circ Res. 2014;115(5):504–17.

18. May D, et al. Transgenic system for conditional induction and rescue of chronic myocardial hibernation provides insights into genomic programs of hibernation. Proc Natl Acad Sci U S A. 2008;105(1):282–7.

19. Rowe GC, et al. Disconnecting mitochondrial content from respiratory chain capacity in PGC-1-deficient skeletal muscle. Endocr Rev. 2006;27(7):728–35.

20. St-Pierre J, et al. Bioenergetic analysis of peroxisome proliferator-activated receptor gamma coactivators 1alpha and 1beta (PGC-1alpha and PGC-1beta) in muscle cells. J Biol Chem. 2003;278(29):26597–603.

21. Rowe GC, et al. PGC-1beta regulates angiogenesis in skeletal muscle. Am J Physiol Endocrinol Metab. 2011;301(1):E155–63.

22. Chinsomboon J, et al. The transcriptional coactivator PGC-1alpha mediates exercise-induced angiogenesis in skeletal muscle. Proc Natl Acad Sci U S A. 2009;106(50):21401–6.

23. Wagner BK, Arany Z. High-throughput real-time PCR for detection of gene-expression levels. Methods Mol Biol. 2009;486:167–75.

24. Arany Z, et al. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha. Nature. 2008;451:1008–12.

25. Rowe GC, et al. PGC-1alpha induces SPP1 to activate macrophages and orchestrate functional angiogenesis in skeletal muscle. Circ Res. 2014. in press.

26. Motterlini R, Otterbein LE. The therapeutic potential of carbon monoxide. Nat Rev Drug Discov. 2010;9(9):728–43.

27. Otterbein LE, Foresti R, Motterlini R. Heme oxygenase-1 and carbon monoxide in the heart: the balancing act between danger signaling and pro-survival. Circ Res. 2016;118(12):1940–59.

28. Pyrtel SW, Alam J, Choi AM. Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. Physiol Rev. 2006;86(2):583–650.

29. Kawahara G, et al. Dystrophic muscle improvement in zebrafish via increased heme oxygenase signaling. Hum Mol Genet. 2014;23(7):1869–78.

30. Kawahara G, et al. Dystrophic muscle improvement in zebrafish via increased heme oxygenase signaling. Hum Mol Genet. 2015;24(15):4480–1.

31. Shy Y, et al. Role of Bach1 and Nrf2 in up-regulation of the heme oxygenase-1 gene by cobalt protoporphyrin. FASEB J. 2006;20(14):2651–3.

32. Yoshida T, et al. H(mox-1) constitutes a n adaptive response to effect antioxidant cardioprotection: a study with transgenic mice heterozygous for targeted disruption of the heme oxygenase-1 gene. Circulation. 2001;103(12):1695–701.

33. Motterlini R, et al. CORM-A1: a new pharmacologically active carbon monoxide-releasing molecule. FASEB J. 2005;19(2):284–6.

34. Bathoorn E, et al. Anti-inflammatory effects of inhaled carbon monoxide in patients with COPD: a pilot study. Eur Respir J. 2007;30(6):1131–7.

35. Schallner N, Otterbein LE. Friend or foe? Carbon monoxide and the mitochondria. Front Physiol. 2015;6:17.

36. Wegiel B, et al. Carbon monoxide expedites metabolic exhaustion to inhibit tumor growth. Cancer Res. 2013;73(23):7009–21.

37. Rhodes MA, et al. Carbon monoxide, skeletal muscle oxidative stress, and mitochondrial biogenesis in humans. Am J Physiol Heart Circ Physiol. 2009;297(1):H392–9.

38. Picorella SR, et al. The HO-1/CO system regulates mitochondrial-capillary density relationships in human skeletal muscle. Am J Physiol Lung Cell Mol Physiol. 2015;309(8):L857–71.